Rock Springs Capital Management’s Blueprint Medicines BPMC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-185,500
| Closed | -$23.8M | – | 95 |
|
|
2025
Q2 | $23.8M | Sell |
185,500
-822,069
| -82% | -$85.4M | 1.48% | 26 |
|
|
2025
Q1 | $89.2M | Sell |
1,007,569
-89,330
| -8% | -$8.71M | 5.1% | 3 |
|
|
2024
Q4 | $95.7M | Buy |
1,096,899
+328,123
| +43% | +$30.1M | 3.64% | 5 |
|
|
2024
Q3 | $71.1M | Sell |
768,776
-1,691,641
| -69% | -$168M | 2.31% | 8 |
|
|
2024
Q2 | $265M | Sell |
2,460,417
-38,031
| -2% | -$3.81M | 7.98% | 1 |
|
|
2024
Q1 | $237M | Sell |
2,498,448
-383,119
| -13% | -$32.9M | 6.02% | 1 |
|
|
2023
Q4 | $266M | Buy |
2,881,567
+196,273
| +7% | +$12.7M | 6.54% | 1 |
|
|
2023
Q3 | $135M | Buy |
2,685,294
+498,622
| +23% | +$26.6M | 3.61% | 5 |
|
|
2023
Q2 | $138M | Buy |
2,186,672
+153,624
| +8% | +$8.35M | 3.29% | 5 |
|
|
2023
Q1 | $91.5M | Buy |
2,033,048
+141,538
| +7% | +$6.38M | 2.18% | 12 |
|
|
2022
Q4 | $82.9M | Buy |
1,891,510
+353,315
| +23% | +$16.9M | 1.99% | 15 |
|
|
2022
Q3 | $101M | Buy |
1,538,195
+559,021
| +57% | +$35.9M | 2.62% | 9 |
|
|
2022
Q2 | $49.5M | Buy |
979,174
+31,459
| +3% | +$1.84M | 1.44% | 23 |
|
|
2022
Q1 | $60.5M | Buy |
947,715
+87,960
| +10% | +$6.31M | 1.52% | 21 |
|
|
2021
Q4 | $92.1M | Buy |
859,755
+10,096
| +1% | +$1.06M | 2.13% | 11 |
|
|
2021
Q3 | $87.4M | Buy |
849,659
+40,799
| +5% | +$3.8M | 1.84% | 15 |
|
|
2021
Q2 | $71.1M | Buy |
808,860
+62,128
| +8% | +$5.69M | 1.41% | 18 |
|
|
2021
Q1 | $72.6M | Sell |
746,732
-95,268
| -11% | -$9.51M | 1.58% | 20 |
|
|
2020
Q4 | $94.4M | Sell |
842,000
-110,773
| -12% | -$11.7M | 2% | 8 |
|
|
2020
Q3 | $88.3M | Sell |
952,773
-7,256
| -0.8% | -$559K | 2.24% | 6 |
|
|
2020
Q2 | $74.9M | Buy |
960,029
+223,029
| +30% | +$15.1M | 2.05% | 5 |
|
|
2020
Q1 | $43.1M | Buy |
737,000
+355,000
| +93% | +$22.8M | 1.78% | 13 |
|
|
2019
Q4 | $30.6M | Buy |
382,000
+48,500
| +15% | +$3.63M | 0.97% | 38 |
|
|
2019
Q3 | $24.5M | Buy |
333,500
+26,000
| +8% | +$2.25M | 0.98% | 34 |
|
|
2019
Q2 | $29M | Buy |
307,500
+32,500
| +12% | +$2.68M | 1.05% | 30 |
|
|
2019
Q1 | $22M | Buy |
275,000
+61,342
| +29% | +$4.53M | 0.85% | 41 |
|
|
2018
Q4 | $11.5M | Buy |
213,658
+13,658
| +7% | +$830K | 0.54% | 59 |
|
|
2018
Q3 | $15.6M | Buy |
200,000
+1,000
| +0.5% | +$69.5K | 0.57% | 62 |
|
|
2018
Q2 | $12.6M | Buy |
199,000
+41,247
| +26% | +$3.28M | 0.49% | 71 |
|
|
2018
Q1 | $14.5M | Buy |
157,753
+11,253
| +8% | +$970K | 0.62% | 62 |
|
|
2017
Q4 | $11M | Buy |
146,500
+60,000
| +69% | +$4.22M | 0.5% | 71 |
|
|
2017
Q3 | $6.03M | Buy |
+86,500
| New | +$4.62M | 0.28% | 96 |
|
Other funds holding BPMC
IA
HNB
Rock Springs Capital Management's BPMC Position: Q3 2025 in Review
Rock Springs Capital Management sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 185,500 shares — an estimated $23.8M sold.
Rock Springs Capital Management first reported a position in BPMC in Q3 2017 and held it in 32 quarters. The position peaked at $266M in Q4 2023. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.
- Rock Springs Capital Management reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
- Rock Springs Capital Management sold 185,500 Blueprint Medicines shares in Q3 2025, an estimated $23.8M.
- Rock Springs Capital Management first reported a position in Blueprint Medicines in Q3 2017 and held it in 32 quarters.
- Rock Springs Capital Management's Blueprint Medicines position peaked at $266M in Q4 2023.
- 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.
Based on Rock Springs Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.